Breaking News

AlphaRx, Gaia BioPharma Secure CMO

AlphaRx Inc.’s licensee, Gaia BioPharma Ltd., has signed an agreement with a CMO to manufacture GAI-122 for use in Phase I and II trials.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AlphaRx Inc.’s licensee, Gaia BioPharma Ltd., has signed an agreement with a CMO to manufacture GAI-122 for use in Phase I and II trials. GAI-122 is being developed as an injectable nanoemulsion formulation to potentially to treat patients with acute ischemic stroke or to prevent postoperative delirium. “We are very pleased with the progress of the GAI-122 development program; it is on track to enter human trials in 2010,” said Michael Lee, president and chief executive officer of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters